Home › Burkitt-lymfoom › Oklahoma › Oklahoma City
Burkitt-lymfoom klinische studies in Oklahoma City, OK
7 studies voor Burkitt-lymfoom zoeken deelnemers op locaties in en rond Oklahoma City (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruterenFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RekruterenFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RekruterenFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruterenFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekruterenFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruterenFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
RekruterenFase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Burkitt-lymfoom studies in andere steden
- Houston, TX21 studies
- Philadelphia, PA16 studies
- Milwaukee, WI16 studies
- Chicago, IL15 studies
- Cincinnati, OH13 studies
- New York City, NY13 studies
- Atlanta, GA12 studies
- Aurora, CO11 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Boston, MA10 studies
- Kansas City, MO10 studies
Andere studies in Oklahoma City
- Niet-kleincellige longkanker28 studies
- Eierstokkanker28 studies
- Endometriumkanker25 studies
- Colorectale kanker22 studies
- Prostaatkanker21 studies
- Longkanker19 studies
- Borstkanker17 studies
- Metastatische kanker16 studies
- Kanker (alle vormen)14 studies
- Acute myeloïde leukemie14 studies
- Plaveiselcelcarcinoom van hoofd en hals13 studies
- Blasenkanker11 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.